DBMG yields 3.63% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, DBMG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DBMG + ABBV for your $10,000?
DBM Global Inc., together with its subsidiaries, operates as steel fabrication and erection contractor in Canada, Australia, New Zealand, India, the Philippines, Thailand, the United Kingdom, and the United States. The company offers integrated structural and steel construction services; and professional services, including design-assist/design-build, pre-construction design and budgeting, steel management, fabrication, erection, and 3D building information modeling. It also fabricates trusses and girders; provides fabrication and erection of large-diameter water pipe and water storage tanks; provides integrated solutions for digital engineering, modeling and detailing, construction, and heavy equipment installation, as well as facility services, including maintenance, repair, and installation. In addition, the company manufactures pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators, and various customized products. It provides its services for projects in a range of markets that comprise commercial, industrial, and infrastructure construction projects, such as high- and low-rise buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills, and power plants. The company was formerly known as Schuff International, Inc. and changed its name to DBM Global Inc. in September 2016. DBM Global Inc. was incorporated in 2001 and is based in Phoenix, Arizona. DBM Global Inc. is a subsidiary of HC2 Holdings, Inc.
Full DBMG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.